Zobrazeno 1 - 5
of 5
pro vyhledávání: '"929"'
Autor:
Oscar Arrieta, R. Bernabé, Judith Dalmau, Miguel Angel Molina-Vila, Jorge Carrillo, Remedios Blanco, Teresa Moran, Clara Mayo de las Casas, Jillian Wilhelmina Paulina Bracht, Bonaventura Clotet, Christian Brander, Jordi Argilaguet, Julia G. Prado, Mariano Provencio, Javier Garcia-Corbacho, Ana Giménez-Capitán, Mónica Garzón, Erika Aldeguer, Andrés F. Cardona, Rafael Rosell, Bartomeu Massuti, Javier de Castro, Maria Gonzalez-Cao, Javier Martinez-Picado, Andreas Meyerhans, Sonia Rodríguez, Oscar Juan, Ana Drozdowskyj, Chung-Ying Huang, J. Blanco
Publikováno v:
Cancer Research. 80:929-929
Introduction: Treatment with anti PD-1/PD-L1 antibodies has demonstrated clinical activity in different types of solid tumors, but only 20 to 30% of patients (pts) respond to these immune checkpoint inhibitors (ICIs). Therefore, predictive biomarkers
Autor:
Bradley M. Turner, Danielle E. Desa, Edward B. Brown, Brandon Buscaglia, Robert L. Strawderman, Robert L. Hill, David G. Hicks
Publikováno v:
Cancer Research. 79:P6-09
Background: Over-expression of Human Epidermal Growth Factor receptor-2 (HER2) in breast cancer is associated with an aggressive clinical course and poor prognosis. Targeting HER2 over-expression has been shown to be a remarkably effective therapeuti
Autor:
Katarzyna Jozwiak, GS Sonke, P. J. Van Diest, E. E. van der Wall, Sabine C. Linn, Michael Hauptmann, Gmhe Dackus, Sabine Siesling
Publikováno v:
Cancer Research. 77:P2-09
Background This study is part of the Netherlands Breast Cancer Project, initiated to address research questions that are unlikely answered by future randomized controlled trials (RCT). Here we investigated whether aromatase inhibitors (AI) are superi
Autor:
Antonio Antón, Rachel Wuerstlein, Suzette Delaloge, P Button, Carlos Barrios, N Lindegger, Peter M. Ellis, Filippo Montemurro
Publikováno v:
Cancer Research. 77:P1-12
Introduction T-DM1 treatment significantly improved overall survival and had a lower incidence of grade ≥3 adverse events (AEs) vs capecitabine plus lapatinib in patients (pts) with HER2-positive advanced breast cancer (BC) in the EMILIA study, inc
Publikováno v:
Cancer Research. 69:4105
Abstract #4105 Introduction: The decision to treat women with hormone receptor-positive breast cancer with chemotherapy in addition to hormonal therapy is complex. Models have been developed to assist physicians in estimating survival benefit associa